Targeted Delivery of Methotrexate to Tumor Cells Using Biotin Functionalized Methotrexate-Human Serum Albumin Conjugated Nanoparticles
Systemic toxicity following cancer chemotherapy is an important concern. Targeted drug delivery systems could reduce the toxicity of anticancer drugs. Vitamins have been considered as targeting moieties in novel cancer treatment strategies. In this study, biotin was attached to nanoparticles
of conjugated methotrexate-human serum albumin. Biotin functionalized methotrexate-human serum albumin with three different amounts of biotin attached to the nanoparticles were prepared. It was shown that the cytotoxicity of biotin functionalized nanoparticles on T47D and HeLa tumor cells
was significantly higher than that of free methotrexate and non-functionalized nanoparticles. The cytotoxicity of biotin functionalized nanoparticles further increased when the number of biotin molecules attached on the surface of nanoparticles increased. The uptake of FITC labeled biotin
functionalized nanoparticles by T47D and HeLa cells measured by flow cytometry, was also higher than that of non-functionalized nanoparticles. It can be concluded that the biotin functionalized methotrexatehuman serum albumin conjugated nanoparticles could be used as a potent drug for specific
delivery of methotrexate to tumors.
Keywords: BIOTIN; CANCER; HUMAN SERUM ALBUMIN; METHOTREXATE; NANOPARTICLES; TARGETED DRUG DELIVERY
Document Type: Research Article
Publication date: 01 December 2011
- Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
- Editorial Board
- Information for Authors
- Subscribe to this Title
- Terms & Conditions
- Ingenta Connect is not responsible for the content or availability of external websites
- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content